SponsoredContent

Treatment strategies for metastatic hormone‑sensitive prostate cancer are evolving rapidly, but guidelines often lag clinical practice. Leveraging data from US community urology practices, this analysis shows how real‑world evidence can reveal the use of new therapies in patient populations typically underrepresented in trials.

Download the case study